Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have received an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $6.8750.

A number of brokerages have recently issued reports on SRTS. Maxim Group reduced their price target on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research report on Tuesday, April 21st. Citigroup reaffirmed a “buy” rating on shares of Sensus Healthcare in a research report on Friday, May 8th. Alliance Global Partners initiated coverage on shares of Sensus Healthcare in a report on Friday, March 6th. They set a “buy” rating and a $7.50 price objective on the stock. Finally, Wall Street Zen downgraded shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th.

Sensus Healthcare Stock Performance

Shares of Sensus Healthcare stock opened at $2.70 on Wednesday. The company has a market capitalization of $44.44 million, a PE ratio of -5.74 and a beta of 1.09. The company has a 50-day simple moving average of $3.69 and a two-hundred day simple moving average of $4.07. Sensus Healthcare has a one year low of $2.66 and a one year high of $5.92.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, May 7th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The firm had revenue of $3.39 million during the quarter, compared to the consensus estimate of $5.32 million. Sensus Healthcare had a negative return on equity of 15.79% and a negative net margin of 34.50%.

Hedge Funds Weigh In On Sensus Healthcare

Hedge funds have recently modified their holdings of the stock. Opes Wealth Management LLC purchased a new stake in shares of Sensus Healthcare during the third quarter valued at $50,000. XTX Topco Ltd purchased a new position in Sensus Healthcare in the 4th quarter worth $77,000. Jane Street Group LLC purchased a new stake in Sensus Healthcare during the 4th quarter valued at about $79,000. Mindset Wealth Management LLC grew its stake in Sensus Healthcare by 28.1% during the 3rd quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock valued at $157,000 after purchasing an additional 11,000 shares during the last quarter. Finally, Ingalls & Snyder LLC purchased a new stake in Sensus Healthcare during the 4th quarter valued at about $219,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.